{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:31:33Z","timestamp":1760783493952},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T00:00:00Z","timestamp":1326844800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s10120-011-0135-0","type":"journal-article","created":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T09:02:39Z","timestamp":1326790959000},"page":"427-432","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy"],"prefix":"10.1007","volume":"15","author":[{"given":"Takayuki","family":"Ando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kajiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Itaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Fujinami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tsukioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Yabushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Note","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,18]]},"reference":[{"key":"135_CR1","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137\u201350.","journal-title":"J Clin Oncol"},{"key":"135_CR2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3322\/canjclin.49.1.33","volume":"49","author":"DM Parkin","year":"1999","unstructured":"Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33\u201364.","journal-title":"CA Cancer J Clin"},{"key":"135_CR3","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ctrv.2010.01.005","volume":"36","author":"DG Power","year":"2010","unstructured":"Power DG, Kelsen DP, Shah MA. Advanced gastric cancer\u2014slow but steady progress. Cancer Treat Rev. 2010;36:384\u201392.","journal-title":"Cancer Treat Rev"},{"key":"135_CR4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547\u201353.","journal-title":"J Clin Oncol"},{"key":"135_CR5","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063\u20139.","journal-title":"Lancet Oncol"},{"key":"135_CR6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"135_CR7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10120-011-0009-5","volume":"14","author":"H Narahara","year":"2011","unstructured":"Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301\/TOP-002). Gastric Cancer. 2011;14:72\u201380.","journal-title":"Gastric Cancer"},{"key":"135_CR8","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Cutsem Van","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991\u20137.","journal-title":"J Clin Oncol"},{"key":"135_CR9","first-page":"269","volume":"4","author":"JA Ajani","year":"1998","unstructured":"Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998;4:269\u201374.","journal-title":"Cancer J Sci Am"},{"key":"135_CR10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00001813-199804000-00003","volume":"9","author":"S Cascinu","year":"1998","unstructured":"Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 1998;9:307\u201310.","journal-title":"Anticancer Drugs"},{"key":"135_CR11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00000421-199808000-00021","volume":"21","author":"A Ohtsu","year":"1998","unstructured":"Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 1998;21:416\u20139.","journal-title":"Am J Clin Oncol"},{"key":"135_CR12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1023\/A:1011680507956","volume":"12","author":"Y Yamada","year":"2001","unstructured":"Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001;12:1133\u20137.","journal-title":"Ann Oncol"},{"key":"135_CR13","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"AD Seidman","year":"2008","unstructured":"Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26:1642\u20139.","journal-title":"J Clin Oncol"},{"key":"135_CR14","first-page":"2667","volume":"27","author":"Y Kodera","year":"2007","unstructured":"Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 2007;27:2667\u201371.","journal-title":"Anticancer Res"},{"key":"135_CR15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10120-009-0524-9","volume":"12","author":"R Shimoyama","year":"2009","unstructured":"Shimoyama R, Yasui H, Boku N, Onozawa Y, Hironaka S, Fukutomi A, et al. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer. 2009;12:206\u201311.","journal-title":"Gastric Cancer"},{"key":"135_CR16","first-page":"4845","volume":"51","author":"MC Bissery","year":"1991","unstructured":"Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991;51:4845\u201352.","journal-title":"Cancer Res"},{"key":"135_CR17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","volume":"5","author":"J Verweij","year":"1994","unstructured":"Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 1994;5:495\u2013505.","journal-title":"Ann Oncol"},{"key":"135_CR18","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.1998.16.10.3362","volume":"16","author":"V Valero","year":"1998","unstructured":"Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998;16:3362\u20138.","journal-title":"J Clin Oncol"},{"key":"135_CR19","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/annonc\/mdg292","volume":"14","author":"G Aravantinos","year":"2003","unstructured":"Aravantinos G, Bafaloukos D, Fountzilas G, Christodoulou C, Papadimitriou C, Pavlidis N, et al. Phase II study of docetaxel\u2013vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol. 2003;14:1094\u20139.","journal-title":"Ann Oncol"},{"key":"135_CR20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1159\/000217264","volume":"76","author":"A Sella","year":"2009","unstructured":"Sella A, Yarom N, Zisman A, Kovel S. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology. 2009;76:442\u20136.","journal-title":"Oncology"},{"key":"135_CR21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00001813-200009000-00003","volume":"11","author":"YC Lin","year":"2000","unstructured":"Lin YC, Chang HK, Wang CH, Chen JS, Liaw CC. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel. Anticancer Drugs. 2000;11:617\u201321.","journal-title":"Anticancer Drugs"},{"key":"135_CR22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-004-2184-0","volume":"89","author":"K Yonemori","year":"2005","unstructured":"Yonemori K, Katsumata N, Uno H, Matsumoto K, Kouno T, Tokunaga S, et al. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast Cancer Res Treat. 2005;89:237\u201341.","journal-title":"Breast Cancer Res Treat"},{"key":"135_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/030089160409000109","volume":"90","author":"M Sawaki","year":"2004","unstructured":"Sawaki M, Ito Y, Hashimoto D, Mizunuma N, Takahashi S, Horikoshi N, et al. Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori. 2004;90:36\u20139.","journal-title":"Tumori"},{"key":"135_CR24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1075-122X.2004.21555.x","volume":"10","author":"T Taguchi","year":"2004","unstructured":"Taguchi T, Aihara T, Takatsuka Y, Shin E, Motomura K, Inaji H, et al. Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J. 2004;10:509\u201313.","journal-title":"Breast J"},{"key":"135_CR25","first-page":"1915","volume":"25","author":"T Taguchi","year":"1998","unstructured":"Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced\/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho. 1998;25:1915\u201324.","journal-title":"Gan To Kagaku Ryoho"},{"key":"135_CR26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10147-008-0775-1","volume":"13","author":"M Fujii","year":"2008","unstructured":"Fujii M. Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol. 2008;13:201\u20135.","journal-title":"Int J Clin Oncol"},{"key":"135_CR27","unstructured":"Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol (Epub ahead of print)."},{"key":"135_CR28","first-page":"2863","volume":"29","author":"G Matsuda","year":"2009","unstructured":"Matsuda G, Kunisaki C, Makino H, Fukahori M, Kimura J, Sato T, et al. Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer. Anticancer Res. 2009;29:2863\u20137.","journal-title":"Anticancer Res"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-011-0135-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10120-011-0135-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-011-0135-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T15:44:19Z","timestamp":1561218259000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10120-011-0135-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,18]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["135"],"URL":"https:\/\/doi.org\/10.1007\/s10120-011-0135-0","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,18]]}}}